文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

联合检查点阻断与靶向治疗时代免疫介导性心肌炎的深入探讨

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.
PubMed 文献 · Eur J Cancer · 2020-01-01

该系列描述了6例接受抗PD-1或抗PD-L1抗体联合MAPK抑制剂治疗的晚期黑色素瘤患者发生免疫介导性心肌炎,表现从无症状心肌酶升高到心力衰竭死亡不等。心脏MRI对心肌炎早期检测敏感,5例有典型改变而其中2例超声心动图正常;接受免疫抑制的5例中4例恢复、1例死于心衰。

要点

  • ICI联合MAPK抑制剂治疗中免疫介导性心肌炎表现异质,可从无症状酶升高至致死性心衰。
  • 心脏MRI可早期检测心肌炎,5例有特征性改变而其中2例超声心动图正常。
  • 临床需警惕、多模态诊断和多学科管理免疫介导性心肌炎。

核心结论

  • ICI联合MAPK抑制剂治疗的晚期黑色素瘤患者可发生免疫介导性心肌炎,临床表现异质且可能致命。
  • 心脏MRI是早期检测和监测心肌炎症的敏感无创工具,可在超声心动图正常时发现异常。
  • 临床警惕、及时多模态诊断和多学科管理对免疫介导性心肌炎至关重要。

研究设计与样本

  • 该系列描述了6例接受抗PD-1抗体或抗PD-L1抗体联合丝裂原活化蛋白激酶抑制剂治疗的晚期黑色素瘤患者。
  • 回顾了这些患者的异质性临床表现、检查发现和治疗结局。

主要发现

  • 临床表现从无症状心肌酶升高到因心力衰竭死亡不等。
  • 6例中5例心脏MRI显示心肌炎特征性改变,包括壁内心肌水肿和非冠状动脉分布延迟钆增强。
  • 这5例中2例超声心动图结果正常。
  • 接受免疫抑制治疗的5例中4例心肌炎恢复、1例死于心脏衰竭。
  • 第6例仅通过心力衰竭管理改善;对ICI应答的4例中3例获得长期获益。

临床怎么用

  • 对接受ICI联合MAPK抑制剂治疗的患者应保持临床警惕,及时识别免疫介导性心肌炎。
  • 利用心脏MRI等多模态诊断工具早期检测和监测心肌炎症,即使超声心动图正常也不应排除。
  • 采用多学科管理,包括免疫抑制和心力衰竭管理,以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have transformed the management of many malignancies. Although rare, immune-mediated myocarditis presents unique clinical challenges due to heterogenous presentation, potential life-threatening consequences, and the time-critical need to differentiate it from other causes of cardiac dysfunction. Increasingly, TKI are being combined with ICI to promote immune modulation and improve efficacy. However, these combinations are associated with more toxicities. This series describes six patients with advanced melanoma who developed immune-mediated myocarditis while receiving an anti-PD-1 antibody or an anti-PD-L1 antibody plus a mitogen-activated protein kinase inhibitor. It provides a review of their heterogenous clinical presentations, investigational findings and treatment outcomes. Presentations ranged from asymptomatic cardiac enzyme elevation to death due to heart failure. We highlight the role of cardiac MRI (CMRI), a sensitive and non-invasive tool for the early detection and subsequent monitoring of myocardial inflammation. Five of the six patients exhibited CMRI changes characteristic of myocarditis, including mid-wall myocardial oedema and late gadolinium enhancement in a non-coronary distribution. Critically, two of these patients had normal findings on echocardiogram. Of the five patients who received immunosuppression, four recovered from myocarditis and one died of cardiac failure. The sixth patient improved with cardiac failure management alone. Three of the four patients responding to ICI derived long-term benefit. Clinical vigilance, prompt multimodal diagnosis and multidisciplinary management are paramount for the treatment of immune-mediated myocarditis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Guo CW, Alexander M, Dib Y, et al. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer. 2020. PMID: 31707280. doi:10.1016/j.ejca.2019.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。